SCHEMBL7144950

SCHEMBL7144950

O=C(O)C[C@@H]1C[C@@H](SC(c2ccccc2)(c2ccccc2)c2ccccc2)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.42
AKR1C1 Q04828 1/20 0.42
MCL1 Q07820 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCR4 P51679 4/20 0.38
HPGD P15428 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144954 1.00 AKR1C3 (0.42) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5409323 0.90 AKR1C3 (0.41) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5409316 0.90 AKR1C3 (0.41) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5403975 0.90 AKR1C3 (0.39) AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2
SCHEMBL5403980 0.90 AKR1C3 (0.39) AKR1C3AKR1C1LMNAALDH1A1SMN1; SMN2
SCHEMBL5416660 0.88 AKR1C3 (0.42) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5416668 0.88 AKR1C3 (0.42) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5399164 0.88 LMNA (0.40) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5405204 0.88 LMNA (0.40) AKR1C3AKR1C1MCL1LMNAALDH1A1
SCHEMBL5399163 0.88 LMNA (0.40) AKR1C3AKR1C1MCL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP AKR1C3 1685/4885AKR1C1 1596/4885MCL1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.